undamentalytics Newsletter

Stahl Neil: insider trades

Officer at Regeneron Pharmaceuticals. No open-market purchases and 19 sales not made under a pre-set plan, reported from February 15, 2012 to February 8, 2024.

What happened after Stahl Neil’s sales?

After their sales, the shares moved +20.4% against the index over 12 months on average (a negative figure means selling was the right call); 26% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Stahl Neil: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 19 +2.8% −2.1% 53% 11 0.45 0.66 No reliable evidence
Sales, 12 months after the report 19 +20.4% +28.9% 26% 11 0.38 0.71 No reliable evidence
Sales, 12 months after the trade 19 +19.7% +26.5% 26% 11 0.22 0.83 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Regeneron Pharmaceuticals REGN EVP Research and Development019February 15, 2012February 8, 2024

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
February 8, 2024February 7, 2024 REGN Sale $7,637,954 −2.1%−52.3%−49.4%
August 23, 2023August 22, 2023 REGN Sale $9,810,082 −8.3%+14.1%+12.6%
August 8, 2022August 5, 2022 REGN Sale $14,569,134 +28.0%+17.3%+16.9%
May 18, 2021May 17, 2021 REGN Sale $9,101,460 +17.3%+32.6%+27.5%
May 11, 2020May 11, 2020 REGN Sale $3,021,289 −9.2%−52.7%−56.6%
November 26, 2019November 26, 2019 REGN Sale $1,458,467 +26.6%+20.8%+22.0%
November 12, 2019November 8, 2019 REGN Sale $2,492,888 +5.0%+43.4%+49.1%
May 15, 2019May 14, 2019 REGN Sale $3,012,483 −4.3%+85.7%+88.1%
May 25, 2018May 24, 2018 REGN Sale $3,366,092 +22.8%−1.9%−0.2%
November 9, 2015November 6, 2015 REGN Sale $23,637,627 −23.2%−31.9%−38.6%
November 24, 2014November 21, 2014 REGN Sale $2,191,425 −2.1%+32.9%+37.7%
August 11, 2014August 11, 2014 REGN Sale $3,959,204 +8.2%+61.2%+57.6%
August 8, 2014August 7, 2014 REGN Sale $967,644 +6.1%+57.6%+59.9%
February 13, 2014February 13, 2014 REGN Sale $7,209,136 −11.5%+8.3%+6.2%
May 14, 2013May 13, 2013 REGN Sale $6,378,806 −14.1%−9.4%−17.4%
December 3, 2012November 30, 2012 REGN Sale $3,110,114 −15.2%+28.9%+38.3%
November 21, 2012November 21, 2012 REGN Sale $4,245,442 −15.1%+36.1%+26.5%
August 30, 2012August 29, 2012 REGN Sale $2,460,647 +21.5%+61.3%+59.4%
February 15, 2012February 14, 2012 REGN Sale $5,709,687 +22.2%+36.0%+34.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Stahl Neil traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.